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 FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
and Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
Colorectal cancer spreads to the liver and the frequency of this metastatic event is high with 
around 25% of patients having liver metastases at the time of presentation (synchronous 
metastases) and a further 25-50% of patients developing liver metastases some time during 
the course of their disease (metachronous metastases). 
 
The standard treatment for patients with hepatic metastases is systemic chemotherapy. This is 
typically administered using drug regimens based on 5-fluorouracil (5-Fu), which offer modest 
prolongation of survival, although very rarely leading to a cure, with 5-year survivals reported 
at less than 5% by the majority of advanced colorectal chemotherapy trials. 
 
Other experimental treatments for liver metastases include local ablation with arterial 
chemotherapy, embolisation or cryotherapy and surgical removal. With the exception of 
surgery, none of these treatments has appeared to provide any real impact in terms of 
overall survival and long-term cure. 
 
Historically, surgical removal, or resection, of liver metastases has been restricted to only a 
small percentage of patients who have had single, unilobar metastasis because of the 
technical difficulties of the resection.  
 
There are no published randomised controlled trials which directly compare the role of liver 
resection against standard treatments for liver metastases.  However, there have been a 
large number of reported case-series spanning a period of over two decades. This review 
identified 21 independent studies involving more than 100 patients in each case. 
 
Based on the reported survival outcomes for the treated populations as a whole, five year 
survival following surgical resection ranges between 21-41% (compared with <5% survival in 
similar patients without such surgical intervention). The best prognosis group are those with 
single metastases, without evidence of extrahepatic involvement. However, sub-group 
analysis with case-series suggests that, despite the number and size of tumours, there are 
clear survival advantages for patients with multiple metastases if the resection can 
successfully remove all of the metastases without leaving positive margins. The more 
recent, larger single centred studies report operative mortality rates of around 0-4% and 
post operative complications rates of 10-30%. 
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Although some patients already have access to liver resection, particularly in cases of single 
metastases, it is widely felt that there are many more patients who could benefit potentially 
who remain either undiagnosed or are receiving purely palliative treatment. 
 
The costs of liver resection are estimated at £6,402 which covers initial work-up, the surgical 
procedure and the post-surgical management of patients. The typical systemic 
chemotherapy for non-resected patients is based on 5-FU and is estimated to cost £2,223 
per month, with an average three to six months’ treatment per patient. 
 
The estimated marginal costs of providing liver resection within a ‘typical’ health authority of 
500,000 population are £130-135,000, based on an estimated 10% of patients being 
suitable for resection. This assumes that there is no avoidance of chemotherapy costs. In 
some cases, however, surgical resection would obviate the need for palliative 
chemotherapy. 
 
Excluding any savings that may be made through avoided chemotherapy treatment, and 
assuming no differences in salvage treatment for relapses, the cost per life year gained 
(LYG) for liver resections lies in the range £2,134 to £3,945 per LYG. This figure is 
dependent on the actual proportion of resections which can be performed with curative 
intent. The range quoted covers 100% to 50% of resections having curative intent and 
reflects the range of reported experience from case-series. 
 
If widespread follow-up of colorectal patients were to be adopted, in the light of improved 
survival following liver resection, then it is likely that cost-effectiveness will increase by an 
estimated 50% (based on 5-year survival rates and an estimated cost of follow-up including 
6-monthly out-patient attendances and ultrasound scans). 
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ABBREVIATIONS 
 
5-FU 5-Fluorouracil 
AUC Area under the curve 
BNF British National Formulary 
CEA Carcino-embryonic antigen 
CT Computed tomography 
CXR Chest x-ray 
ECR Extra Contractual Referral 
EHD Extrahepatic disease 
FUDR Floxuridine 
HAI Hepatic arterial infusion 
HDU High dependency unit 
HRG Health Care Resource Group 
ITU Intensive treatment unit 
 LV Leucovorin 
LYG Life year gained 
MRI Magnetic resonance imaging 
MTO 3 Medical Technical Officer Grade 3 
PIS Patient information system 
RCT Randomised controlled trial 
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1. INTRODUCTION 
 
1.1 Background 
 
Primary cancer of the large bowel - colon and rectum - is the second commonest cancer in the 
United Kingdom overall with an annual incidence rate of around 57 per 100,000 population per 
annum.
1
 Colorectal cancer spreads to the liver and the frequency of this metastatic event is 
high.  Around 25% of patients who present with colon and rectal cancer have liver metastases 
at the time of presentation (synchronous metastases). Up to a further 25-50% of patients will 
develop recurrent tumour in the liver during the course of their disease (metachronous 
metastases), typically during the first two years following the treatment of the primary 
cancer.
2,3,4
  
 
Liver metastases are seen as a major cause of death in patients with colorectal cancer.
4
 
Overall survival for patients with liver metastases is closely related to tumour burden, and 
untreated patients with single unilobular disease have previously had a median survival of 
around 21 months.
5
 However, the long-term outlook for all such untreated patients, including 
both single and multiple lesions, is universally recognised as poor with little or no observed five 
year survival.  
 
Conventional treatments for such liver metastases have either been purely palliative or have 
involved a range of techniques including: systemic chemotherapy; local ablation with arterial 
chemotherapy; embolisation or cryotherapy and surgical removal.  With the exception of 
surgery, none of these treatments has appeared to provide any real impact in terms of 
overall survival and long-term cure.  Because of the recognised difficulties in operating on 
the liver (bleeding etc.), surgical removal has been restricted historically to only a small 
percentage of patients who have had single, unilobular metastasis.   
 
More recent advances in surgical techniques, coupled with the relative lack of success in 
non-surgical treatment, has led to an increasing number of more specialist centres operating 
on a wider group of patients including those with multiple metastases and bilobar disease. 
Overall survival, following liver resection at such centres, has been suggested to be 
between 25-35% at five years, with a gradual improvement noted in survival and morbidity 
over the last 10-15 years since such treatment has been available. Importantly, this more 
aggressive liver resection can leave patients requiring significant post-surgical care involving 
high cost Intensive Therapy Unit (ITU) provision.  
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However, despite the numerous reported case-series, there remains as yet no conclusive 
randomised controlled trial (RCT) which can clearly define the likely benefits of liver 
resection for a particular patient group. The proportion of patients who may be suitable for 
resection remains heavily debated. Many of the published studies attempt to identify 
independent prognostic factors which may help to categorise levels of expected outcome for 
patient groups. In particular, the most helpful of these prognostic factors would be those 
which can be identified before the surgery has begun. Unfortunately, whilst some prognostic 
factors are well accepted, such as the presence of extra-hepatic disease, others, such as 
the actual number and position of the metastases, are more contentious. 
 
Although some patients already have access to liver resection, particularly in cases of single 
metastases, it is widely felt that there are many more patients who could benefit potentially 
who remain either undiagnosed or are receiving purely palliative treatment. 
 
The purpose of this guidance note is to identify and review the current state of evidence for 
the effectiveness of liver resection in cases of metastases related to colorectal primary 
lesions. Where possible, it draws on the likely characteristics of good prognosis groups and 
the likely impact that such patients may have on NHS resources. Finally, the authors 
consider the additional primary research which may be required to address the unanswered 
issues of liver resection, such as the role of more complex surgery, indications for re-
resection and the justification for the use of adjuvant chemotherapy as well as follow-up of 
colorectal cancer patients. 
 
1.2  Surgical Resection of Secondary Liver Cancer 
 
In the early years since its inception, this type of surgery was not very common because of a  
high operative mortality and morbidity. Over the past 10 years, however, significant 
technological progress has been made in liver resection, with better understanding of the 
anatomy of the liver and the physiological and metabolic consequences of major hepatic 
resections. The advent of intra-operative ultrasonography, ultrasonic dissection, and argon 
spray coagulation have made it possible to resect large amounts of liver tissue without 
significant complications.  Furthermore, the liver is perhaps the only solid organ with the ability 
to regenerate completely after resection of even a large percentage of its volume. 
 
For many years the criteria for selection of patients for liver resection for colorectal cancer was 
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considered to be a single metastasis on one or other side of the liver which could be removed 
surgically with a margin of at least 1cm. This is still the practice in most general hospitals in the 
UK at present. With technological advancement, some surgeons have extended the criteria to 
include two to three metastases from one or other lobes of the liver.  More recently, specialist 
liver surgeons have successfully resected fairly extensive disease from both sides of the liver 
with reports of long-term survival.  
 
1.2.1 Technical Aspects of Hepatic Resection 
 
The human liver is a solid organ anatomically situated in the upper abdomen underneath the 
diaphragm.  Morphologically, it is divided into the right and left lobes demarcated by the 
falciform ligament (Figure 1).  
 
Figure 1   The Lobar Structure of the Liver 
 
The liver has a dual blood supply, approximately 80% of the supply comes from the hepatic 
portal vein which drains blood from most of the gastro-intestinal tract, and 20% from the 
hepatic artery which is a branch of the coeliac artery (arising from the aorta).  It is an extremely 
vascular organ with 1.5 litres of blood passing through it each minute (30% of the cardiac 
output). 
 
There are eight anatomical segments in the liver, segments I, II and III lie to the left of the 
falciform ligament and are supplied by the left branch of the hepatic portal vein and hepatic 
artery.  Segment IV lies to the right of the falciform ligament and is also supplied by the left 
hepatic portal vein and hepatic artery.  Segments V, VI, VII and VIII lie entirely on the right side 
with segments V and VI lying below VII and VIII and supplied by the right branch of the hepatic 
portal vein and hepatic artery. (Figure 2). 
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Figure 2  The Segmental Structure of the Liver 
 
Hepatic resections are classified according to the site of the segments removed.  Anatomical 
resections are further complicated because the nomenclature used is morphological.  These 
are shown in Table 1. There is a different nomenclature in use in North America, which 
compounds the confusion and will not be discussed here. 
 
As a general rule, anatomical resections are associated with shorter operating time, lower 
blood loss and quicker recovery with a low risk of liver failure. Extended resections, 
especially right-sided ones, are associated with a significant risk of liver failure especially if 
the size of segments II and III is small, however, the development of selective portal vein 
embolisation has allowed pre-resection hypertrophy and significantly reduces the risk of liver 
failure despite very extensive resection.  
 
Table 1 Nomenclature of Hepatic Resections  
Type of Resection Segments Removed Anatomical or Extra-anatomical 
Right hemi-hepatectomy V,VI, VII and VIII Anatomical 
Left hemi-hepatectomy II and III Anatomical 
Extended right hemi-hepatectomy IV, V, VI, VII and VIII Extra-anatomical 
Extended left hemi-hepatectomy I,II,III and IV Extra-anatomical 
‘Central’ resection IV with or without I Extra-anatomical 
‘Segmental’ resections Any segments (single or in 
combination of adjoining segments) 
in a single lobe except I and IV 
Anatomical 
‘Bilobar’ resections Any segment in both lobes Extra-anatomical 
‘Wedge’ resections Any segment, superficial tumour Extra-anatomical 
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These resections are described in the following illustrations for easier comprehension:
 
 
Right hemi-hepatectomy 
 
 
Left hemi-hepatectomy 
 
 
Extended left hemi-hepatectomy  
 
 
 
 
 
 
 
 
Extended right hemi-hepatectomy 
 
 
Bilobar resection 
 
 
Wedge resection 
1.3 Non-surgical Treatment of Secondary Liver Cancer 
 
The lack of clear benefit from the non-surgical treatment of hepatic metastases from colorectal 
cancer has meant that many patients have been managed symptomatically without attempt to 
'cure'. This review has not attempted to evaluate the evidence of clinical effectiveness of the 
range of alternative treatments which are on offer, but in the review of effectiveness reference 
has been made to a number of case-series reporting survival for patients who did not receive 
surgery.  In assessing the marginal costs and benefits of liver resection a direct comparison 
has been made with systemic chemotherapy. 
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1.3.1 Chemotherapy  
 
A detailed discussion of the role of chemotherapy in colorectal cancer is beyond the scope 
of this document. In summary, chemotherapy is offered to patients with colorectal cancer in 
two settings, adjuvant and palliative. 
 
Adjuvant chemotherapy: 
Adjuvant chemotherapy is given to patients after resection of the primary colonic or rectal 
cancer and is usually offered to patients with locally advanced (Dukes C) cancers diagnosed 
on histological examination of the resected specimen.  This has a ‘prophylactic’ value and 
has been clearly shown to reduce recurrence and improve survival in this group of patients.  
The ‘De Gramont’ regime with 5-fluorouracil (5-FU) and folinic acid (leucovorin) is currently 
favoured. 
 
Palliative chemotherapy: 
Palliative chemotherapy is given to patients who have the following: 
 Locally advanced colonic cancers and the colorectal surgeon is unable to clear 
completely the primary tumour;  
 Patients who have synchronous liver metastases which have not been resected; 
 Patients who have recurrent abdominal or lung tumours. 
 
The aim of therapy in this group of patients is to prolong survival and alleviate symptoms, 
although there is no good evidence that either of these goals are achieved.
6
 
 
The choice of therapy depends upon whether the patient has already been given 5-FU as 
adjuvant treatment, in which case alternative drugs (e.g. Tomudex or oxaliplatin) may be 
considered.  
 
In the UK, probably the most common form of 5-FU palliative treatment is the ‘De Gramont’ 2-
day regimen. This is based around a daily treatment involving an initial combined 2-hour 
infusion of leucovorin (200mg/m
2
) + bolus 5-FU (400mg/m
2
)  followed by a 22-hour infusion of 
5-FU (400mg/m
2
). This regimen is typically repeated every 14 days. A  patient may face an 
average of six cycles of therapy (i.e. a three month active treatment period). An alternative 5-
day ‘Mayo’ 28-day cycle regimen can also be used in some cases, with slight differences in 
toxicity and drug dosage. 
 
20 
Chemotherapy for liver metastases may also be delivered locally via a hepatic arterial infusion 
catheter (HAI). The advantages of HAI lie in the more direct administration of chemotherapy 
drugs to the liver, potentially minimising systemic exposure. A number of trials have reported 
response and potential survival advantages over systemic chemotherapy and no treatment. 
However, within the UK the use of HAI would still be regarded as experimental and would not 
be available outside of a clinical trial.
4,6,7
 
 
Other treatments which may be given alone or in combination with surgery include: 
 
1.3.2 Cryotherapy   
 
Cryotherapy utilises rapid freezing of the tumour.  The abdomen is opened and a cryotherapy 
probe is placed in the centre of the liver metastases. An ice-ball is then formed which is 
allowed to thaw; one or more freeze/thaw cycles are used to achieve a significant degree of 
tumour destruction. 
  
1.3.3 Interstitial Laser Therapy  
 
Interstitial laser therapy utilises the delivery of energy to the core of the metastases in order to 
heat the metastases with a view to destruction. The principles are the same as for 
cryotherapy; instead high temperature is used for destroying tumours. 
 
1.3.4 Interstitial Radiation 
 
Radiation delivered directly to the metastases by implanted radioactive seeds is another 
approach to controlling tumour growth. 
 
1.4 Scale of the Problem in a ‘Typical’ District  
 
The incidence of colorectal cancer (ICD-10: C18/C20) has been recorded at 54.8 per 
100,000 population per annum for the Trent region during 1992/94.
8
 Given an estimated  
population of 4.6 million for this period, this represents approximately 2,650 reported cases 
per annum  (270 cases for a ‘typical’ health authority population of 500,000). This level of 
incidence fits well with nationally reported rates of 59.5 per 100,000 (male) and 56.3 per 
100,000 (female).
1
  
 
21 
The incidence and mortality rates for colorectal cancer have remained steady over the last 
15 years, with only a slight reduction in observed mortality rates (Figure 3). Recorded cases 
of colorectal cancer are apparent from around 35-40 years of age and increase with age 
steadily, showing a consistently slightly higher incidence in males than females.  
 
Figure 3  Trent Colorectal Cancer Statistics 
Trends in Incidence and Mortality in Trent: Colorectal Cancer
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Around 25% of colorectal patients will present with liver metastases diagnosed at the same 
time as the primary tumour (synchronous cases). Around 25-50% of patients will develop 
liver metastases some time after the primary surgery, typically within a 2-year period 
(metachronous cases). Therefore, within the Trent region around 2,000 new cases of liver 
metastases, directly related to a primary colorectal cancer would be expected. For a ‘typical’ 
health authority of 500,000 population, these figures equate to an expected 270 new cases 
of colorectal cancer each year, with an estimated 210 cases involving liver metastases (70 
synchronous/140  metachronous).  
 
It is possible that these numbers are over-estimations due to the high percentage of patients 
with colorectal cancer being elderly and the fact that some might, therefore, be unfit for 
major surgical resections due to significant co-morbidity. Age alone should not be a contra-
indication to surgery due to improved outcomes with the use of modern anaesthesia and 
post-operative care. 
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In trying to determine the best way to manage these patients a key question is which 
patients, if any, should receive surgery. The historical clinical view has been that between 5-
10% of liver metastases cases are resectable. This implies that within the Trent region there 
are between 100-200 cases of liver metastases which are potentially resectable. However, 
more recent case-series from specialist centres have utilised much wider eligibility criteria 
and, potentially, this could expand the proportion of patients suitable for resection to 20-
25%. 
 
In an attempt to try to identify the number of patients undergoing liver resection (as defined 
by a J02 procedure code) a search of the Trent Patient Information System (PIS) database 
1996/97 was conducted. Initially, the analysis was restricted to patients coded as having 
colorectal primaries. This revealed just four patients undergoing liver resection, of whom 
only two had a diagnosis coding of secondary liver metastases. The analysis was expanded 
to include any patient who had either a coding of secondary liver or primary colorectal 
cancer, as it was felt that coding omissions might explain the low number. This second, 
wider search, revealed 21 patients undergoing liver resection in the Trent region during 
1996/97.  
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2. HEPATIC RESECTION AS A TREATMENT FOR LIVER METASTASES IN 
COLORECTAL CANCER: SUMMARY OF EVIDENCE OF EFFECTIVENESS  
 
2.1 Literature Search Strategy  
 
In searching the literature relevant to the treatment of metastases from colorectal primaries, 
the authors considered all reported reviews and case-series of liver resection over an initial 
period covering 1990 to July 1998.  
 
The search focused on the following data bases: 
 MEDLINE; 
 EmBASE; 
 COCHRANE LIBRARY; 
 HMIC (Dept of Health/ King’s Fund/ HELMIS); 
 CRD (DARE/NEED/HTA databases); 
 20-25 other information sources, covering web sites, personal contacts and literature 
databases. 
 
Precise search terms, used in the main searches of Medline and EmBase for evidence of 
liver resection, are provided below. 
 
EmBASE 1/1990-7/1998 
No.    Records     Request  
   1      28472     explode ‘COLON-CANCER’/ all subheadings  
   2      18384     explode ‘RECTUM-CANCER’/ all subheadings  
   3      32620     #1 or #2  
   4        7063     ‘LIVER-METASTASIS’/ all subheadings  
   5        5088     ‘LIVER-CANCER’/ all subheadings  
   6      27909     ‘METASTASIS’/ all subheadings  
   7         226     #5 and #6  
   8        7271     #4 or #7  
   9        5175     explode ‘LIVER-RESECTION’/ all subheadings  
  10         317     #3 and #8 and #9  
  11         228     #10 and (PY >= "1990")  
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MEDLINE 1/1990-7/1998 
1     exp colonic neoplasms/ or exp rectal neoplasms/      24,067 
2     exp Liver neoplasms/                                               20,139 
3     Hepatectomy/                                                        3,338 
4     resection.ti.                                                       6,331 
5     3 or 4                                                            9,051 
6     ((liver or hepatic) adj6 metast$).tw.                      5,789 
7     1 and 2 and 5                                                        334 
8     1 and 6 and 5                                                        301 
9     7 or 8                                                                        348 
10    (animal not human).sh.                                       699,672 
11    9 not 10                                                                    342 
12    from 11 keep 1-342                                                   342 
13    from 12 keep 1-342                                                   342 
 
As a result of the review of this evidence, particularly previous reviews of liver resection, the 
search was expanded to include case-series dating back to 1984. This was felt necessary 
as many of the more recent reviews were still referencing larger series reported from this 
earlier period. 
 
In total 59 case-series were found which reported on the use of liver resection in cases of 
metastases related to colorectal primary cancer.  As resection represents a fairly specialised 
surgical technique it was felt justified to concentrate on case-series which reported survival 
results in more than 100 patients. Also, consideration was only given to the latest published 
data covering specific patient cohorts, as in some cases there were multiple reports of case-
series.  
 
Therefore, in total 21 independent case-series were identified, representing different patient 
cohorts, which had sufficient patient numbers (>100) to be able to infer treatment 
consequences in terms of overall survival, operative morbidity and/or pre-operative 
prognostic factors. (see Tables in Appendices.) 
 
2.2 Clinical Effectiveness of Non-surgical Treatment  
 
In evaluating the role of liver resection, it is important to compare results with those 
achieved with no treatment or with other non-surgical treatment modalities. As already 
25 
discussed, the standard alternative treatment for patients with liver metastases is systemic 
chemotherapy based on the use of 5-FU + a modulator, with the most common regimen 
based on the De Gramont dosage/administration combination.  
 
The ideal evidence of effectiveness would be a direct randomised trial of resection against 
standard chemotherapy in patients with potentially resectable liver metastases. However, it 
was not possible to identify any randomised controlled studies which would allow this direct 
comparison to be made. Given the growing world-wide acceptance of the role of liver 
resection, as the only potentially curative treatment for liver metastases, the future 
availability of such randomised comparable data in non-resected patients is very unlikely. 
 
One potential source of indirect comparative data is the existing group of published trials 
which have considered the relative efficacy of different chemotherapy regimens for patients 
with advanced colorectal cancer, often involving liver metastases. This body of data has 
been concerned generally with the comparison of 5-FU with 5-FU + modulator, and 
evaluating the role of HAI against continuous infusion, often using floxuridine (FUDR) rather 
than 5-FU.  
 
A recent Advanced Colorectal Meta-Analysis project considered the efficacy of 5-FU in the 
treatment of patients with measurable non-resectable metastases and no evidence of 
extrahepatic disease.
9
 Covering 1,400 patients from nine trials, the results suggested a 23% 
tumour response rate and an overall median survival of approximately 12 months for 5-FU + 
leucovorin.  
 
The group went on to consider the role of HAI against continuous infusion in a subsequent 
meta-analysis of seven trials covering 654 patients.
10
 The studies compared HAI based 
FUDR with a control arm of either intravenous FUDR / 5-FU or no treatment. Overall, 5-FU 
was associated with a 14% response rate and an overall survival of 12 months. This 
compared with an HAI tumour response rate of 41%. However, the only significant survival 
advantage for HAI was discovered when compared to a no-treatment group.  
 
Allen-Mersh et al.
11
 considered the efficacy of HAI versus conventional chemotherapy in 100 
non-resectable advanced colorectal cancer patients, having no greater than 60% liver 
involvement and no extrahepatic disease (EHD). The HAI group achieved a median survival 
of roughly 13 months compared with seven months for the control group.   
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Scheithauer et al.
12
 considered the relative benefits of 5-FU + leucovorin (LV) + cisplatin in 
40 previously untreated patients with liver metastases or recurrent primary disease. 
Compared with non-chemotherapy supportive care only, chemotherapy was associated with 
a relatively small, but statistically significant, advantage in median survival (11 months 
versus 5 months). 
 
Figure 4 Survival of Advanced Colorectal Patients - Typical Datasets 
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Taken together, this body of data suggests a 12 month overall median survival for patients 
with advanced colorectal disease, with little or no 5-year survival (Figure 4). However, 
although  randomised, the problem with advanced colorectal trial data is that the patient 
group is much broader than those with pure isolated liver metastases. Patients with 
colorectal related liver metastases are currently classified as Dukes Stage D, which also 
encompasses those with much more widespread metastatic disease. These trials tend to 
include a range of Dukes C and D patients. As such, the study populations almost certainly 
include patients with tumour burden and EHD which would exclude them from aggressive 
liver resection.  
 
An alternative is to derive comparative data from resection case-series themselves as 
(1) Advanced Colorectal Meta Analysis Project : 5-FU vs 5-FU + LV (as reported by Benson et al)
2  : HAI vs 5-FU
3 llen-M rsh et al 1994 (included in Meta Analysis Project (2))
4 Scheithauer a 3  
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several of the studies have tried to identify a comparison group, often quoting survival 
outcomes for resected, non-resected and non-curative resected patient groups. It is likely 
that these non-resected patient groups are more suitable for comparison although, clearly, 
in the absence of randomised studies, it is difficult to be confident of comparing like with like.  
Patients going forward for liver resection, even in units which strongly advocate this surgery, 
are highly selected; i.e. without significant comorbidities, surgically fit with a low chance of 
perioperative mortality and a pattern of secondaries which is resectable.  Patients who are 
not operated on, by contrast, include all those rejected for surgery because their tumours 
were too far advanced or they were suffering from other conditions likely to affect the 
outcome adversely. 
 
The most notable attempt to establish a comparable control group for liver resection comes 
from Wagner et al.
5,13
 in a study analysing the fate of 252 unresected patients.  They 
excluded from this group those with extrahepatic spread and significant comorbidities in 
order to create a group which could act as historical controls for patients having resections.  
Even so, the group was likely to have more severe disease than those having resections as 
only 70 had tumours which were judged as resectable.  Median survival for unilobular and 
multilobular lesions was 21 and 15 months respectively.  Over 20% of patients with solitary 
liver lesions lived for three years or more, but very few survived for more than five years 
(Figure 5). 
 
Figure 5  Overall Survival in Cases of Unresected Liver Metastases 
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Source : Excel graph using data taken from published survival curve - Wagner et al.
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By contrast, a recent review of the natural history of patients with untreated liver metastases 
considered the outcome of 172 Swedish patients, all of whom had proven colorectal cancer. 
The original laparotomy enabled a clear diagnosis of synchronous metastases in 155 (91%) 
of these patients. The mean age of the patients was 69 years (range: 35 years - 89 years) 
and, as with many series, a slight bias towards men (83 versus 72) was observed. None of 
these patients had further treatment other than the surgery for the primary tumour. Median 
survival on follow-up was 4.5 months; the longest survival was 36 months. Metachronous 
metastases were observed in 12 of the 172 patients, between 3-26 months following the 
primary tumour surgery.
3
 
 
Stangl et al.
14
 considered the survival experience of 1,099 patients with liver metastases, 
splitting the group into those receiving resection, regional chemotherapy, systemic 
chemotherapy and no-treatment. Overall, median survival was 30 months with only 3% 
(36/1099) achieving a 5-year survival. The curative resection group had a 41% five-year 
survival rate compared to 0-5% for the remaining patient groups. 
 
Wade et al.
15
 analysed the computerised files of the US Department of Veterans Affairs 
Hospitals from 1988 to 1992 representing over one million admissions per year. They 
identified 887 patients whose codes indicated that they had a single liver metastasis which 
was not resected. Mean survival was 11 months, with a projected five-year survival of 2%.  
 
There are clear difficulties in identifying a comparison group which makes drawing firm 
conclusions about the natural history of untreated, or non-surgically treated hepatic 
secondaries very difficult. However, it is clear that, whilst there is variation in quoted 
survivals for these patients for periods of under five years, instances of survival beyond five 
years for such patients are rare. Even in the group likely to do best, those with a single 
unresected metastasis, no literature was identified which reported five-year survival of 
greater than 5%.  
 
The Wade et al. study
15
 appears to provide the most appropriate comparative data, as it is 
stratified by the extent of the liver metastases and the solitary and unilobar group is likely to 
be closest to representing a group of potentially resectable patients. 
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2.3 Clinical Effectiveness of Liver Resection 
 
2.3.1 Quantity and Quality of Evidence 
 
To date there have been no reported randomised controlled trials which directly compare 
the role of liver resection against other treatments. However, there have been a large 
number of reported case-series spanning a period of over two decades. The majority of 
these published case-series involve small numbers, but a core group of significant studies 
was identified, each of which involved more than 100 patients.   
 
Although this group included significant series dating from the mid to late 1980s, including a 
large series from the Mayo clinic (US)
5,13
 and a large multi-centre study from North America 
and England,
16,17
 these tended to have more recently published updates and, as such, they 
have not been included in the summary of effectiveness. Overall, 21 independent case-
series were identified each of which reported survival in over 100 patients. The authors have 
chosen to concentrate on these series on the basis that larger studies represent best 
practice and have more potential to identify significant sub-groups with differing chances of 
survival.  
 
The majority of the studies (20 out of 21) have been published during the last 10 years. 
Most series come from single centres, although there are multi-centre studies from 
France,
18,19
 the Netherlands
20
 and the USA.
15,21,22
  Irrespective of the publication year there 
tends to be  great variation in terms of the precise time-period in which the data were 
collected. A number of the series (9 out of 21) include cases from more than twenty years 
ago.    
 
Some series have methodological problems in that they rely heavily on retrospective 
analysis of computerised records of large population groups. This raises concerns firstly in 
terms of the reliability of such data, and sufficient detail on the type of resection conducted 
is not easily accessible. Others are predominantly retrospective studies which must carry 
caveats in terms of the quality of data collection and control of the patient group.  Only four 
series seem to have explicit prospective data collection.
21,23,24,25
 
 
Basic patient characteristics in these studies are broadly similar with mean age at operation 
around 60 years and similar numbers of men and women. Of more significance are 
differences between the studies in the criteria used for operation and the criteria used for 
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inclusion and exclusion in the reported series.  There are opportunities to exclude patients 
before, during, or even after the operation.  Pre-operative exclusions are designed to 
identify those patients whom the surgeon considers will benefit from surgery. The types of 
test used have changed over time with, for example, the introduction of computerised 
tomography and nuclear magnetic resonance imaging. The criteria used to exclude or 
include patients for surgery also varies widely over time and between centres. This aspect of 
patient selection is a key part of the assessment of the procedure which is discussed in 
Section 2.4 on prognostic indicators.  
 
Most of the series attempted to exclude pre-operatively patients whose cancer had spread 
outside the liver and in whom the tumour was not resectable.  However, the extent to which 
pre-operative investigations are able accurately to identify these patients is hard to assess 
from the literature.  A large series from Erlangen, Germany
25
 reported that of 1,718 patients 
with hepatic metastases, 80% were subjected to laparotomy, of which 64% did not go 
forward to resection. Another study
26
 excluded a further 20% of cases during surgery on the 
basis of intra-operative ultrasound and the surgeons’ view of tumour resectability. Other 
series are not clear about the proportions excluded and may have attempted some sort of 
resection on all the patients selected on pre-operative criteria. In this second instance,  
patients may be classified post-operatively into groups according to whether the tumour 
actually was resected completely  by the surgeon,  either on inspection, or after  microscopic 
examination of the margins of the resected liver. 
 
A further cause of difficulty in comparing studies comes from differences in which patients 
are selected for reporting, and differences in the treatments patients received after 
resection. Clearly some series have given adjuvant therapies to some,
23
 or all patients.
27
 
Some series exclude patients who have had repeat resections
28
 while others include them. 
The 859 resections reported by Hughes et al.
17
 only included those who survived for 30 days 
after operation,  while most other series include perioperative death in their 5-year survival 
data. 
 
The type of  resections reported in the series is yet another variable,  related to the selection 
of patients for surgery, where the complex nomenclature makes it particularly difficult to 
make accurate comparison.  Finally, variation in the length and  completeness of follow-up is 
particularly important where the main outcome measure is survival. Some series claim 100% 
follow-up
23,24,25
 while in others follow-up is either lower or not mentioned.
27
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2.3.2 Patient Survival 
 
The majority of the studies (16 out of 21) focus on five-year actuarial survival as a primary 
measure of outcome, with fewer studies using median survival statistics. Based on the 
reported survival outcomes for the treated populations as a whole, five-year survival ranges 
between 21% and 41%. (See Table 2). 
 
Table 2 Overall 5-Year Survival Rates Following Hepatic Resection 
Ref Potentially 
Curative 
Only 
Sites Years Median 
Survival 
5-Year 
Survival 
Operative 
Mortality 
Operative 
Morbidity 
Fuhrman et al.
26
 Y Y 14 - 44% 2.8% - 
Bakalakos et al.
27
 N Y 15 20 mths - - - 
Fong et al.
29
 Y Y 6 - 38% 2.8% 24% 
Taylor et al.
30
 N Y 16 - 34% 0% 28% 
Scheele et al.
25
 N Y 32 33 mths 33% 4.4% 16% 
Hughes et al.
22
 N N 37 - 33% - - 
Gayowski et al.
31
 Y Y 11 - 32% 0% - 
Doci et al.
32
 N Y 10 28 mths 30% 5% 33% 
Rees et al.
24
 N Y 9 - 30% 1% 17% 
Nordlinger et al.
19
 N N 22 - 28% 2.3% 23% 
Wade et al.
15
 N N 14 31 mths 26% 4% - 
Ohlsson et al.
23
 Y Y 24 25 mths 25% 3.6% 14% 
Jenkins et al.
28
 N Y 18 - 25% 3.8% 18% 
Rosen et al.
33
 Y Y 27 - 25% 2% - 
Van Ooijen et al.
20
 Y N 10 - 21% 7.6% 34% 
Steele et al.
21
 N N 4 37 mths - - - 
 
Despite differences in patient prognostic grouping and overall patient numbers, the general 
pattern is one of improving overall survival rates, peri-operative mortality and morbidity. 
Influences of technical advances in such treatment would appear to explain these 
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improvements particularly as resection has become progressively more aggressive in these 
series. A few studies cover long periods of time allowing the possibility to consider the 
influence of improvements in surgical technique over the last 10-20 years. In a series of 111 
cases from 1971 to 1995 in a single centre in Sweden, the five-year actuarial survival 
increased from 19% in the period up to 1984 to 35% thereafter.
23
  Reporting on 450 
resections, 30 of which were carried out before 1980, Scheele et al. reported only marginal 
differences in five-year survival of 37% and 39% between the two groups, though the 
second group appears to have had more radical surgery.
25
 Whilst it remains difficult to 
attribute definite causal relationships to improvements over time-periods, there appears to 
be some justification for the argument that improvements in surgical technique and post-
surgical care are allowing a comparable level of survival in more complex patients. 
 
Another feature is that the longest five-year survivals are from single centres. The main 
multi-centre studies,
15,19,34
 have five-year survivals of 21%-28%. The more numerous single 
centre studies range from 21% to 44%, which may indicate an effect of surgical expertise 
concentrated in these centres. The spread of the reported five-year survival data, plotted 
against the cohort size of the studies, implies that the largest published studies reflect the 
mid-range of reported survival.  
 
Figure 6  Plot of 5-Year Survival versus Cohort Size 
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2.3.3 Operative Morbidity and Mortality of Resection 
 
Operative mortality has been a problem previously associated with liver resection, with early 
series indicating up to 5-10% of cases resulting in death during the 30-day post-operative 
period. The main causes of mortality following liver surgery tend to relate to bleeding, 
33 
cardiac arrest, sepsis and liver failure. However, when comparing the mortality rates of the 
identified resection case-series, it is seen that there has been a marked improvement in 30-
day mortality rates over the last 10-20 years. The most recent and larger single centred 
studies report mortality rates of around 0-4%, in contrast to the higher 4-8% as reported by 
series from the late 1980s and very early 1990s. (Figure 7 refers). 
 
Again, as some of the larger, and more established, series have run over long periods of 
time, they are able to quote significant reductions in mortality rate, despite having adopted a 
more aggressive approach to their surgery. From a series of over 300 resected patients, 
Scheele et al.
35
 reflect on gradual improvements in mortality rates from 11.5% (pre 1980), to 
3.5% (post 1980) and more recently to 1.8% during 1992-95. Similarly, Ohlsson et al.
23
 
report no cases of operative mortality over the last 10 years, compared to a previous rate of 
6% for their earlier cases.  
 
Figure 7   Peri-operative Mortality Rates versus Annual Resections 
Relationship of Operative Mortality Rate to 
Annual Number of Resections per site
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As a parallel issue, post-operative complications can be relatively common with liver 
surgery. The published series suggest that complication rates range between 10-30% and 
are on the whole completely recoverable and manageable before discharge from hospital.  
 
2.4 Prognostic Indicators 
 
In reporting survival outcome, the majority of the published case-series have reflected on 
the ability to identify good prognostic indicators. The objective is to devise a set of pre-
34 
surgical criteria which can be applied to identify patients most suitable for resection and, 
importantly, to identify those for whom resection would provide little or no benefit. A wide 
range of prognostic factors has been examined. These include factors related to the primary 
tumour, the amount of spread, grade of tumour, operative factors and personal factors. As 
expected, those factors which are associated with a more advanced stage of the tumour 
(both primary and secondary) are associated with lower survival. 
 
Whilst some of the potential factors are generally well supported, such as the presence of 
EHD, others have proven more contentious with real differences of opinion. An example of 
such a debated issue is the relevance of the number of metastases to overall outcome, with 
four or more metastases or bilobar disease often stated as a contraindication.  
Unfortunately, some of the factors found to be good indicators of survival are only 
detectable post- or peri-operatively and, as such, cannot really be used by clinicians to 
influence the decision to conduct a laparotomy. Examples include the histological grade of 
the liver metastasis and the presence of disease in the margins of the resected tumour.  
 
Appendix D summarises the range of prognostic factors which have been considered by the 
key published case-series. The table indicates those factors which reach significance as 
independent factors following multi-variate analysis of survival data. The majority of  studies 
use five-year survival as the main outcome measure, although some have used median and  
disease-free survival.  Again, direct comparison between studies is made difficult as the 
studies differ in their inclusion criteria, with patients excluded from some of the series when 
there are important prognostic factors. Not all studies include patients with clear extra-
hepatic disease, or those in whom it was not possible to resect all the tumour. The following 
identifies the main prognostic factors identified by the case-series analysis and considers 
their relevance to the clinical management of the patient. 
 
2.4.1 Curative versus Non Curative Intent 
 
This issue is in many ways the key to the problem.  The concept of a curative or potentially 
curative resection is frequently used to mean either that at operation the patient appeared to 
be macroscopically free of tumour, or that, in addition to this, the specimen also had clear 
resection margins. Several studies excluded patients unless they had a curative resection.  
Studies where it is possible to examine this can be identified in Appendix B where survival 
data for key sub-groups are given.
21,24,27,26,28
  In  all studies there is a clear difference 
between the two groups.  Where median survival has been quoted, the difference ranges 
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from eight months
27
 to 25 months
25
 survival advantage, and in terms of five-year survival  
the differences are even more marked with the highest five-year survival for the non-curative 
resections reported as only 6%
24
. Caution is needed in interpreting these differences, 
because the two groups are not strictly comparable and the numbers in most studies are 
small. One study where the non-resected group appears most comparable is that reported 
by Scheele et al.
25
 who  identified a group of 65 patients in which there was minimal 
macroscopic or microscopic evidence of the presence of disease after resection.  Median 
survival in this group was 14 months compared with 40 months for the curatively resected 
group.  No patient survived for five years, compared with a 38% actuarial five-year survival 
in the curatively resected group.   
 
2.4.2 Extrahepatic Disease 
 
Most series have attempted to exclude patients with extrahepatic disease by pre-operative 
and intra-operative investigation because of its well recognised contribution to poor 
prognosis. So in the majority of series those patients with EHD disease were identified 
during the course of surgery or in the immediate post-operative period.  Of the nine studies 
where this factor was examined, six found it to be significant in the multivariate analysis and 
two in univariate analysis. In the one study where it was not found to be a significant 
variable, this finding was based on only four cases with EHD
36
.   The magnitude of the effect 
is large with little evidence of survival advantage in the group EHD over those  which are not 
resected.  Most authors conclude that the presence of EHD is an absolute contraindication 
to liver resection for secondary colorectal cancer.   
 
2.4.3 Clear Resection Margins 
 
Another clearly significant prognostic indicator is the presence or absence of tumour in the 
margins of the resection specimen examined histologically.  Again, there is almost universal 
agreement that positive margins are a poor to very poor prognostic factor.  In the only study 
listed in Appendix D where it was not found to be a significant factor, it was nevertheless 
associated with a lower disease-free survival.
37
 The importance of clear resection margins is 
overwhelming, but the influence of margin of clearance on survival is debatable. 
 
2.4.4 Size of Tumour, Number of Metastases and Satellite Lesions 
 
The fundamental difference between the conservative and aggressive approaches to liver 
36 
resection as a treatment for hepatic metastases from colorectal cancer is in the indications 
for operation in terms of the size, number and distribution of metastases. Whilst the 
traditional view is that it is only worth resecting a single small metastasis confined to one 
lobe, the proponents of surgery have put forward a number of extended criteria based on 
the number, size and distribution. For example, authors have variously used: less than three 
metastases; less than four metastases; less than 10cm; unilobar; any number of 
metastases, but not tumours with satellite metastases; any number and distribution of 
metastases as long as they can be resected completely without leaving residual tumour.  
 
Nearly all the studies have examined the issue of whether patients with four or more 
metastases fare worse than those with less than four. Opinion is divided, but there are 
important differences in the way that the studies have been carried out which may account 
for some of the difference. For example, most of the studies which have not found the 
number of metastases to be significant, are those which have also taken the grade of the 
tumour into account in the multiple regression model. Taking the series overall, the majority 
of studies find that the number of  metastases is related to prognosis and the effect in many 
is marked.   Rosen et al.
33
 calculates a five-year survival of 29% for patients with one lesion 
compared with 17% for those with two or three, and 13% for those with four or more. Doci et 
al.
32
 found that the probability of five-year survival for single tumours was 38% compared 
with 16% for multiple, and Fong et al.
29
 estimated a 47% survival for single tumours 
compared with 31% for two to three and 24% for four or more. Taylor et al.
30
 Calculated that 
the relative risk of death in those with two or more metastases compared to a single tumour 
was 2.04. Scheele et al.
38
 by contrast found a much smaller difference, with the five-year 
survival for those with one metastasis being 33%, compared with 27% for those with two or 
more. However, in this series, patients with satellite metastases around a single focus were 
included in the ‘single’ group. As satellite configuration is clearly associated with poor 
prognosis, this may be relevant. Rees et al.
24
 also found no difference in five-year survival 
for resection of more than one metastasis.  
 
A similar picture emerges for the size of metastases where various size categories have 
been examined.  Some large series have found this to be a significant prognostic indicator, 
but equally others have not. There seems to be agreement, however, that the presence of 
satellite metastases is a poor prognostic factor.  Satellite metastases tend to be associated 
with more aggressive, and less well differentiated, types of tumour.  
 
Overall, these studies confirm the view that multiple metastases, larger metastases and 
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satellite lesions do indicate poorer prognosis compared to single, small, non-satellite 
lesions.  In coming to a conclusion about whether they are sufficiently poor indicators of 
adverse outcome to make surgery unwarranted, the authors still have difficulties owing to 
the absence of controlled studies or even careful studies of natural history.  Regrettably, 
there are very few detailed studies which allow such comparison.  
 
One study of more than 200 patients who did not have a resection, concluded that the 
median survivals in those with single and multiple unilobular lesions were 21 and 15 months 
respectively, with more than 20% with unresected solitary lesions surviving three years or 
more.
5
   By comparison, median survivals in those series which have published these data 
for patients having liver resection are: 
 
 28 months in those with less than four metastases and 20 months in more than four;
23
 
 35 months in those with one or two metastases and 39 months in those with three or 
more;
28
 
 45 months in those with one metastasis (27 months with satellites) and 41 months in 
those with two or more independent metastases (18 months with satellites);
25
 
 36 months in those with one metastasis, 26 months for two or three metastases and 28 
months with four or more metastases.
32
 
 
In selected patients who fulfil the various pre-operative and intra-operative criteria for 
surgery, the published case-study data would suggest an increased advantage in the 
median survival of up to approximately 13-26 months. In general, however, because of the 
selection process for surgery, these figures are likely to be overestimates.   
 
In addition, a proportion of patients with resected multiple metastases can be expected to 
survive for five years. This proportion varies from being as high as the estimate for single 
metastases
24,25 
or less than half this figure.
30
 By comparison, very few, if any, people with 
known, unresected, multiple metastases can be expected to survive longer than five years. 
 
2.4.5 Metachronous versus Synchronous Metastases 
 
Some studies have considered the relative outcomes of patients with synchronous and 
metachronous disease, and opinion remains divided.  Synchronous metastases are present 
at the time that the primary is removed. This indicates a more advanced stage of the 
disease and, other things being equal, one might expect that this situation would also be 
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associated with more aggressive tumours. Furthermore, to remove synchronous metastases 
at the same time as the primary is to subject the patient to a much bigger operation at one 
time than in the case of those with metachronous disease, where, by definition the patient is 
receiving two procedures separated by months, if not years. Schlag et al.
39
 concluded that 
outcomes of resection for patients with synchronous metastases are universally poorer than 
for those with metachronous metastases. Synchronous metastases were associated with 
higher rates of multiple recurrence rather than single site recurrences.  Other authors have 
also found that removal of metachronous tumours was associated with longer survivals than 
synchronous ones,
25
 although this has not always been statistically significant
24
. Jenkins et 
al.
28
 report that, among  patients with synchronous metastases, those who had  a liver  
resection at the  same time as the primary fared significantly worse than those in whom 
resection was conducted a few weeks later. Although, in several studies, patients with 
synchronous metastases appear to fare worse than those with metachronous metastases, 
the magnitude of the effect alone is probably not sufficiently large to have a significant 
bearing on the decision as whether to operate or not. 
 
2.4.6 Operative Factors 
 
These include the type of resection - whether it was of an anatomical segment or not, the 
amount of liver removed, the amount of intra-operative blood loss and the use of ultrasound 
dissector. Traditionally, the type of resection and the proportion of liver removed were 
important factors, because of high post-operative mortality associated with major non-
anatomical resections. Although a few series still find these factors to be important 
prognostic variables after taking other factors into account, the majority do not find the type 
of resection or the amount of liver removed to be significant predictors of prognosis.  Three 
studies have found the amount of intra-operative transfusion to be a significant factor, which 
is as expected. Most centres use ultrasound dissection in order to minimise blood loss and 
to provide a better means of removing the lesions. Therefore, operative technique is 
important and this is supported by the tendency of single centres with large numbers of 
cases to report better results than multiple centres with small numbers of cases.     
 
2.5 Rates of Recurrence 
 
The issue of re-resection is a contentious one, and many of the series have reported high 
levels of recurrence (typically within two to three years after the initial resection). Although 
50-70% of patients may be expected to have an eventual recurrence, only 10-15% of 
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patients will be considered for re-resection having liver only involvement. Some centres 
carry out additional resections on those patients who experience a recurrence which meets 
their criteria.  Scheele et al.
25
 carried out 51 re-resections on 434 people who had had a first 
resection ‘with curative intent’. Rees et al.
24
 carried out 7 re-resections from 107 people who 
had had an initial resection. Ohlsson et al.
23
 reported 15 re-resections against  128 initial 
resections. 
 
This low rate of re-resection reflects the limited amount of liver-only metastases found on 
recurrence following colorectal related liver metastases.  
 
2.6 Conclusions 
 
No randomised controlled trial data or comparative group studies exist that examine the 
case for liver resection in the treatment of colorectal liver metastases. The evidence 
available is based on well conducted published case-series of patients, who have had 
resection of hepatic metastases for colorectal cancer, and comparisons are limited to 
historical comparative data about the outcome for patients who have had other forms of 
non-surgical treatment. 
 
In general, uncontrolled, non-randomised observational studies are more associated with 
over/under estimation of treatment effects than those that may be suggested through fully 
randomised controlled trials.
40
 When using observational study evidence, conclusions can 
be drawn using statistical comparisons, such as meta-analysis, however, such methods 
carry dangers in terms of confounding factors and study bias.
41
 
 
Based on the available evidence, there appears to be clear survival advantage for patients 
who have liver resection, provided that the surgery renders the patient tumour free (as far as 
can be judged on the basis of current investigations and microscopic examination of the 
resection margin) and they have no EHD. Although patients with multiple liver secondaries 
probably have a worse prognosis than those with a single metastasis, there is evidence of 
survival advantage from resecting these tumours provided that they have no EHD and all 
the tumour can be removed. The evidence does not provide good support for a survival 
advantage from surgery for patients who have liver resection when there is extrahepatic 
disease or in patients in whom all the tumour is not removed. 
 
There is a significant survival advantage from operative techniques which minimise blood 
40 
loss. 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Analysis of Treatment Costings 
 
3.1.1 Cost of Liver Resection 
 
The treatment pathway for potentially resectable patients is shown in Figure 8. This helps to 
demonstrate the main cost elements of treatment: 
 
a) pre-operative costs including diagnostic work-up - including Magnetic Resonance 
Imaging (MRI) scan and measurement of carcino-embryonic antigen (CEA) levels; 
b) variable costs of the resection procedure itself; 
c) cost of adjuvant therapy (if given - evidence base for this is not conclusive); 
d) longer-term follow-up costs. 
 
Figure 8  Treatment Pathway for Potential Liver Resection Patients 
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The following estimates of average cost are taken from experience of liver resection at the 
Royal Hallamshire Hospital, Sheffield. 
 
Table 3  Cost of Diagnostic Work-up 
Diagnostic Test/Resource Average Usage Total Cost  
Out-patient clinic - new appointment 12 minutes for an E grade nurse 
12 minutes for a consultant 
consumables 
 £2.16 
 £11.76 
 £5.00 
Liver function test - pathology 
CEA - pathology 
Per test 
Per test 
 £4.60 
 £6.45 
MRI  1 body area (including contrast)  £270.00 
Out-patient clinic – follow-up 8 minutes for an E grade nurse 
8 minutes for a consultant 
consumables 
 £1.44 
 £7.84 
 £5.00 
TOTAL WORK-UP COST   £314 
 
Table 4  Cost of Liver Resection Procedure 
Operative Procedure/Resource Average Usage Total Cost 
Pre-operative admission   2 nights @ £275 per night  £550.00 
Theatre list: 
Staffing would be for F, E & A grade theatre 
nurse & an MTO 3 for 5 hrs plus 2 hrs for an E 
grade recovery nurse 
F grade 5 hrs 
E grade 5 hrs 
A grade 5 hrs 
MTO 3    5 hrs 
E grade 2 hrs 
 £73.10 
 £63.96 
 £36.41 
 £70.67 
 £25.58 
Consumables Drugs, medical & surgical & sterile 
services 
 £440.18 
HDU (high dependency unit) care 
14% patients also require initial ITU care 
4 nights  @ £500 per HDU bed/night 
5 nights @ £1300 per ITU bed/night plus 
 £2,000.00 
 £910.00 
Ward stay - 5 nights 5 nights @ £275 per night  £1,375.00 
Pharmacy – drugs and i.v. fluids   £275.00 
TOTAL RESECTION COST   £5,820.00 
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Table 5  Cost of Longer-term Follow-up 
Follow-up Resources Usage Total Cost  
Clinical attendance - review 8 minutes for an E grade nurse 
8 minutes for a consultant 
Consumables 
 £1.44 
 £7.84 
 £5.00 
Clinical attendances – follow-up 
6 monthly for 2 yrs (i.e. 4 attendances) 
 
For 4 attendances - Staffing (over 2 yrs) 
32 minutes for an E grade nurse 
32 minutes for a Consultant 
Consumables 
 
 £5.76 
 £31.36 
 £20.00 
4 attendance each including: 
Liver function pathology test (pathology) 
CEA (pathology) 
CXR (chest x-ray) 
Ultrasound of the abdomen 
 
 
4 tests at £4.60 per test  
4 tests at £6.45 per test  
4 tests at £12.04 per test 
4 tests at £26.03 per test 
 
 £18.40 
 £25.80 
 £48.16 
 £104.12 
TOTAL FOLLOW-UP COST   £268.00 
NB: Out-patient costs calculated on: 
Consultant - Maximum part time - Gross cost £59,245 / E Grade Nurse - Days only - Gross cost 
£19,003 
 
 
Bringing these three cost elements together, an overall estimate for the cost at £6,402 can 
be derived. (see Table 6).  
 
Table 6  Total Average Cost of Resection 
Treatment Phase Total Cost 
Cost of Diagnostic Work-up  £314 
Cost of Resection Procedure  £5,820 
Cost of Long-term Follow-up  £268 
Grand Total  £6,402 
 
Importantly, no cost for potential re-resection has been included within this estimate. For the 
purpose of the analysis, the authors have considered that recurrences would be challenged 
with conventional salvage chemotherapy.  
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Although shown in the general treatment pathway diagram as a theoretical option, the cost 
of adjuvant chemotherapy for patients following resection surgery has not been included. 
Although some reported series have used adjuvant systemic chemotherapy with hepatic 
resections, there is no evidence to establish firmly a clear survival advantage in such cases 
and, as such, this is not current UK practice. 
 
These figures represent bottom-up costings using the typical clinical pathway and procedure 
as experienced at the Royal Hallamshire Hospital, Sheffield. However, it also helps to 
consider the costs from a purchaser's viewpoint, by comparison with Extra Contractual 
Referral (ECR) prices for such liver resection procedures. The NHS 1998 Reference Costs
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list the national average ECR cost for a complex liver procedure (Health Care Resource 
Group (HRG) - Code G02) as £3,756 (50% range: £1,865 to £4,890 / 100% range: £296 to 
£11,530).  
 
However, the key issue with this type of HRG costing is that, due to the relatively low volume 
of liver resections in most centres, the average costs are diluted with the costs of higher 
volume, less complex procedures. Therefore, in such cases of new, low volume, complex 
procedures the ECR prices are often under-estimates of the true cost. 
 
3.1.2 Cost of Conventional Treatment 
 
As previously discussed, the most appropriate comparison of marginal benefits and costs is 
for patients who could potentially have had a resection. For the purpose of this review the 
authors have considered that the alternative treatment for these patients would be systemic 
chemotherapy (administered with palliative rather than curative intent). The typical standard 
chemotherapy regimen adopted in the UK currently is based on 5-FU following a De 
Gramont regimen. 
 
The following table presents the typical treatment costs for a patient following such a 
regimen. The cost structure has been taken from a recent cost-comparison study conducted 
by the Royal Marsden Hospital.
43
 The study recorded patient-specific costs and in-
patient/out-patient costs for 31 patients following the De Gramont regimen, including ward 
stay, chemotherapy drugs, diagnostic tests, consumables and fluids. Current British National 
Formulary (BNF) drug costs
44
 and local in-patient costs have been used to ensure a fairer 
comparability to the liver resection costings. It has also been assumed that treatment is 
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based on six courses of in-patient administered chemotherapy (i.e. three months of 
treatment). This is likely to be an under-estimate as patients can experience between three 
and six months of treatment.  
 
Following this chemotherapy regimen, it is estimated that the total treatment costs would be 
around £6,669 (see Table 7). 
 
Table 7  Costs of Palliative Chemotherapy  
 
Monthly Resource Usage Cost 
4 days in-patient  stay @ £275 per day   £1,100.00 
Tests 
Consumables 
Fluids 
 £195.03 
 £25.92 
 £22.97 
Chemotherapy Drug Costs 
Folinic acid (200mg/m2) 2 hours   
5-FU (400mg/m2) 24 hours 
for 2 day period / repeated every 14 days 
 
Concomitant drugs 
 
 £363.92 
 £39.84 
 
 
 £71.27 
Average cost per month (A)  £2,223 
Average number of months (B)  3 
Total Cost of Treatment (A X B)  £6,669 
 
3.1.3 Marginal Cost of Liver Resection 
 
Accepting the assumptions taken of no adjuvant chemotherapy and identical treatment in 
later recurrences, a nominal marginal cost of therapy can be estimated by comparing the 
two costs. 
 
Cost of Liver Resection and Follow-up (A)  £6,402 
Cost of Standard Chemotherapy Regimen (B) £6,669 
Marginal Cost Saving (B-A)       £267 
 
However, it is debatable whether the cost of resection does actually displace the cost of 
chemotherapy. As most patients have recurrence, and the majority of these will be 
challenged with systemic chemotherapy, it could be argued that resection simply delays the 
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original cost of the chemotherapy until a later date (typically two to three years later). 
Therefore, the only potential saving would be if those patients who had a liver resection did 
not have post-hepatectomy chemotherapy and remained free of tumour.  
 
3.2 Analysis of Treatment Benefits 
 
The typical calculations of patient benefits for new drugs/interventions involve the use of 
either median survival data (usually quoted as a trial outcome), or mean survival data 
(typically calculated via area under the curve (AUC) methods of survival curve analysis) 
again taken from published controlled trial evidence.  However, in the case of liver resection, 
there is no such controlled trial evidence available, although there is a relatively large 
number of case-series reflecting variations in patient groups, surgical techniques and 
outcome measurement. Therefore, the authors are faced with a difficult decision in selecting 
an appropriate observational evidence base with which to estimate clinical benefit. 
 
It would seem logical to use case-series which reflect adequately the real life practice of liver 
resection, rather than a limited analysis of curative only procedures, particularly as there will 
be real costs incurred in following up non-curative or non-resection patients.  
 
As such, a case-series was selected which was felt to provide a balance in terms of patient 
numbers, proportion of patients treated curatively, the complexity of the surgical procedures 
adopted, and availability of full survival curve data.  
 
Scheele et al.
25
 report on a large number of patients, of whom 79% had resections of 
anatomical segments, representing what many clinicians would consider to be the leading, 
and most complete, case-series on liver resection for metastases. 
 
If the data are restricted to the first five years of survival (i.e. no continued cure is assumed 
beyond five years), the overall mean survival for patients undergoing resection with curative 
intent is 38 months. Stratifying the population by number of metastases, and the presence 
of EHD, it can be seen that for cases of less than four metastases the mean survival period 
is 39 months compared with 35 months for four or more metastases. This difference was 
found to fall short of reaching statistical significance (p=0.18). The comparative figures using 
data for the full ten years are 53 months, 57 months and 50 months respectively. The 
Scheele data have clearly shown that long-term survival beyond five years is achievable and 
sustainable. This is further confirmed from the study of long-term survivors conducted by 
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D’Angelica.
36
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Figure 9   Survival Following Liver Resection 
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In terms of a comparative set of non-resected survival data, Wagner et al.
5
 have been used 
as a source of expected outcome in a similar patient group treated with standard 
chemotherapy. Based on an AUC approach, the survival curves have been analysed (Figure 
9) and the following mean survivals are estimated: solitary 28 months, multiple unilobar 19 
months, widespread 14 months. 
 
Although there are no randomised trial data comparing liver resection to alternative case-
series against established control groups, derived from either other large natural history 
case-series or data from chemotherapy comparison studies (i.e. 5-FU vs. 5-FU + modifiers 
vs. HAI trials). Whilst this is clearly not ideal, the magnitude of the advantage of liver 
resection is clear even when using the most optimistic outcome for standard treatment (as in 
Wagner et al.).
5
 
 
In their analysis the authors matched less than four metastases and no EHD Scheele group 
with the non-resected multi-unilobar Wagner group. The more than four and/or EHD 
Scheele group was matched with patients having widespread disease.  
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Figure 10  Marginal Survival of Liver Resection versus Chemotherapy 
Survival Following Liver Resection (Scheele et al. 1995) versus 
Non-Resection (Wagner et al. 1984)
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Table 8  Marginal Survival in Cases of Liver Resection 
No. of 
Metastases 
Wagner et al. 
Mean Survival 
Scheele et al.  
Mean Survival 
Difference in Survival 
 
  5 Years’  
Data 
10 Years’  
Data 
5 Years’ 
Data 
10 Years’ 
Data 
Less than 4  19 months 39 months 57 months 20 months 38 months 
4 or more 13 months 35 months 50 months 22 months 37 months 
 
For patients with less than four metastases, the data suggest that over the first five years 
each patient will have a marginal survival of 1.6 LYG over traditional chemotherapy, 
increasing to 3.2 LYG when using all 10 years’ data. For patients with four or more 
metastases, the figures are 1.8 LYG and 3.0 LYG respectively. A similar analysis comparing 
non-resected patients having solitary metastases suggests a 10-year marginal survival 
benefit of 2.1 LYG. 
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3.2.1 Sensitivity of Benefit Calculation 
 
As the survival curves for patients having liver resection suggest a much longer-term 
survival, compared to the non-resected patient groups, there is a clear argument that patient 
benefits beyond the published 10 year limit should also be considered. Indeed, as part of the 
Scheele case series analysis, actuarial 20-year survival rates of over 17% have been 
reported for patients undergoing potentially curative resection. 
 
As part of a sensitivity analysis, the authors of the Guidance Note extrapolated beyond the 
study data by fitting mathematical curves to the published resection survival data, and 
extended these out to a 20 year horizon. As there appeared to be a significant plateau in the 
survival data, suggesting a longer-term curative effect with a reducing hazard rate over time, 
they fitted an exponential survival curve form. Figure 11 shows the extrapolated fitted curve 
for the resected and non-resected patient groups, having <4 metastases and no EHD.  
 
Figure 11   Extended Survival Curves 
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As previously stated, the 5-year survival rates for non-resection patients are <5% and there 
is clinically no expectation of any survival at 20 years. However, in order to provide a 
conservative view of resection, curve fitting procedures were also performed and 20-years' 
survival data extrapolated using the published data for non-resection patients, as suggested 
by Wagner.  
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The results of this extended analysis are shown in Tables 9 and 10, and have also been 
calculated at a discounted rate of 6%. The results clearly show that, if the principle of 
extrapolating out to include 20-year survival is accepted, then marginal benefits can 
increase by around 100% from 5-year survival benefits. 
 
Table 9   Survival Benefits for Patients with 4 or more Metastases and/or EHD 
Survival 
Period 
Wagner et al. Scheele et al. 
 
Difference in Overall 
Survival 
 Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
5-years 
1.1 1.1 2.7 2.9 1.6 1.8 
10-years 
1.1 1.1 3.4 4.1 2.3 3.0 
20-years 
1.1 1.1 3.8 5.0 2.8 3.9 
 
Table 10   Survival Benefits for Patients with less than 4 Metastases and no EHD 
Survival 
Period 
Wagner et al. Scheele et al. 
 
Difference in Overall 
Survival 
 Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
Discounted 
(6%) 
LYG 
Not 
Discounted 
LYG 
5-years 
1.6 1.6 2.9 3.2 1.4 1.6 
10-years 
1.6 1.6 3.9 4.7 2.3 3.1 
20-years 
1.6 1.6 4.6 6.4 3.1 4.8 
 
3.3 Analysis of Cost-effectiveness 
 
In assessing the cost-effectiveness of an intervention, the most common approach is to use 
a measure of mean or median survival for a patient group and to combine this with the 
average cost of the intervention to calculate a cost-effectiveness ratio, typically the cost per 
LYG.  
 
However, in this case it is also important that the proportion of patients who may be 
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accepted for potential resection, but will eventually have either an abandoned procedure 
(due to peri-operative findings such as positive resection margins) or who may have a non-
curative palliative resection, is taken into account. In these cases it is likely that patients will 
be offered chemotherapy as an alternative treatment as well as incurring all or part of the 
costs of resection, without gaining the LYG benefit associated with curatively resected 
patients.  
 
Estimates of the likely proportion of such patients are difficult to make. The published case-
series are varied in their reporting of such cases, with many of the series restricting survival 
data to curative resections only. However, the paper by Rees et al.
24
 may reflect the closest 
estimate to a typical UK specialist centre with referral and entry criteria resulting in 17% of 
patients having no-curative therapy. 
 
Table 11 considers the worst, best and most-likely scenarios involving patients who are 
referred for liver resection, but who are not eventually resected. For non-curative resections, 
the full cost of work-up and the surgical resection procedure have been included, but not the 
follow-up costs, as it is assumed that these patients will move on to standard palliative care. 
For patients in the non-resected treatment group, the costs of work-up and the cost of 
surgery have been included, but only five nights of general post-operative stay. Again, 
follow-up costs are not included. 
 
It is assumed that these patients will receive the same chemotherapy regimen that they 
would have received had they not been considered for resection. Therefore, no additional 
costs for any adjustment to the chemotherapy regimen have been assumed. It is assumed 
that these patients will receive no additional benefit beyond that experienced as 
chemotherapy only patients. 
 
As there is some debate over potential savings through avoided chemotherapy, the liver 
resections have been costed without any off-set against alternative treatment. This, in effect, 
takes the conservative assumption that all resected patients will eventually relapse, and that 
there will be no true long-term disease-free survival. Therefore, the marginal cost of 
resection is assumed to be the complete cost, as estimated at £6,402 (including follow-up). 
 
Expected benefits have been taken for the five years following resection only, at 
approximately three LYG (Table 8 refers). This is very much a conservative view against 
resection. If further extended benefits are included beyond the five-year survival point (i.e. 
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10-years, or even 20-year survival expectations), then the estimated benefits could be 
between 3.5-5 LYG. 
 
The cost-effectiveness has been calculated using undiscounted benefits. However, 
discounted benefit data from Table 9 and Table 10 can be used to repeat the calculation. As 
the costs of resection are all within the first year of treatment, discounting is not required for 
costs. 
 
From Table 11 it is clear that, compared with many other health care interventions provided 
by the NHS, the cost-effectiveness of liver resection is favourable. 
 
It is unlikely that the costs of referral for patients unsuited for liver resection will damage this 
cost-effectiveness argument. Even if 50% of patients were found eventually to be unsuited 
for surgery, or only received palliative resection, the survival benefits for the remaining 
patients are likely to cost around £4,000 per LYG, with an average curatively resected 
patient expected to benefit by three years’ extended survival. For a reasonable proportion of 
patients this survival is likely to extend well beyond five years. Using Rees et al.
24
 as an 
example of UK clinical practice, around 20% of referred patients might not be expected to 
proceed to a full curative resection, leading to a cost per LYG figure of around £2,600. 
 
One issue that also needs to be factored into this consideration is the potential cost of the 
regular follow-up of all patients after colorectal surgery. Whilst previous reports have 
concluded that there is no cost-effectiveness argument for the regular follow-up of such 
patients, it is clear that in many cases clinicians are conducting such follow-up. Typically, 
this is based around six monthly assessments through an ultrasound and a CEA level test, 
usually for a period of two years, within which most metastases are expected to appear.  
 
If liver resection was to become more widely available, it is likely that colorectal follow-up 
would be implemented, particularly if the scope for curative surgery continues to widen.  The 
published literature suggests that the proportion of patients with liver metastases who are 
potentially resectable is 5-10%.  
 
The scenario in Table 12 assumes that all patients are followed up for a two year period. 
Costs are estimated at £320 (i.e. £80 per session covering the out-patient clinic attendance 
at £52 and CEA test/ultrasound at £30). It is also assumed that 10% of patients are 
potentially resectable (i.e. will be referred) and that only 50% of cases will proceed to 
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curative resection at laparotomy, with 40% having non-curative surgery and 10% no 
resection at laparotomy (i.e. the worst-case scenario of the referral patterns from Table 11). 
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Table 11  Costs and LYG Benefits of Potentially Resectable Patients 
 ‘Best Case’ Scenario 
Treatment Group Proportion of 
Patients 
Cost  LYG Cost per LYG 
Curative 100% £6,402 3.0 £2,134 
Non-curative 0% £6,134 0 - 
No resection 0% £2,624 0 - 
Average patient £6,407 3.0 £2,134 
 
‘Likely UK Experience’ Scenario 
Treatment Group Proportion of 
Patients 
Cost  LYG Cost per LYG 
Curative 83% £6,402 3.0 £2,134 
Non-curative 17% £6,134 0 - 
No resection 0% £2,624 0 - 
Average patient £6,619 2.5 £2,658 
 
‘Worst-Case’ Scenario 
Treatment Group Proportion of 
Patients 
Cost  LYG Cost per LYG 
Curative 50% £6,402 3.0 £2,134 
Non-curative 40% £6,134 0 - 
No resection 10% £2,624 0 - 
Average patient £5,917 1.5 £3,945 
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Again, benefits have been limited to undiscounted five-year survival differences. 
 
 
Table 12  Inclusion of Follow-up Costs 
Patient Group Patient Numbers Unit Cost Total Cost 
Colorectal patients follow-up  2,000  £320  £640,000 
Patients referred 10% of 2,000 = 200 patients  
Curative resections  50% of 200 = 100  £6,402  £640,200 
Non-curative resections  40% of 200 = 80  £6,134  £490,720 
No resections  10% of 200 = 20   £2,624  £52,480 
Total cost of resection and follow-up   £1,823,400 
LYG 100 curative patients at 3.00 LYG  300 LYG 
Cost per LYG   £6,078 
 
It is clear, therefore, that regular follow-up decreases the cost-effectiveness and, thus, the 
evidence for its usefulness should be carefully considered if it is to be instituted.  Even so, 
the cost-effectiveness ratio, of around £6,000 per LYG, is well within the range of those for 
other interventions routinely provided by the NHS. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
The options for purchasers can be summarised as: 
 
Option 1: To Fund Resection in Cases of Single Metastasis Only. 
 
 Health authorities should commission services which allow the identification and surgical 
treatment of those patients in whom the removal of liver metastases from colorectal 
cancer have the best predicted outcome and for whom there is a long established 
agreement that they benefit from surgery. This is the group of patients with a single small 
metastasis confined to one lobe.  
 
 The surgical treatment of patients outside of this group should not be purchased. 
 
 This option would still require a significant expansion of current services. Consideration 
would need to be given to having a district level capacity for such surgery or at least 
several centres within the health region. 
 
Option 2: To Fund Resections for a Wider Set of Indications (which include the 
presence of Multiple Metastases) for Which Curative Resection can be Realistically 
Achieved.  
 
 In addition to option 1, health authorities should commission, on the basis of agreed 
criteria, surgery for an additional group of patients who have multiple or large 
metastases. These criteria should probably include: absence of extrahepatic disease, 
absence of other significant comorbidities, pre-operative assessment suggesting that the 
tumour can be removed with clear resection margins, intra-operative assessment 
suggesting that the tumour can be removed with clear resection margins. 
 
 The surgical treatment of patients who do not fall within the criteria in this option should 
only be commissioned as part of properly conducted research studies, designed to 
evaluate the effectiveness of the procedure in comparison with alternative treatments. 
 
 This option would require an even greater expansion of current services. In order to avoid 
inequities in service provision during the expansion of the service to fulfil this option, 
there would have to be strict application of the criteria. 
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Option 3: To Maintain the Status Quo. 
 
 The current situation is that very few patients with liver metastases, who could potentially 
benefit from hepatic resection (even those who meet the traditional criteria of a single 
metastasis) actually receive surgery. This is partly because treating physicians may have 
a lack of awareness of the value and availability of hepatic resection. 
 
Option 4: Not to Fund Liver Resections and Target Only 5-FU Based Chemotherapy 
Regimens. 
 
 This option would involve patients being treated with 5-FU based chemotherapy regimens 
only. Patients could be entered into ongoing trials covering chemotherapy regimes 
(including HAI-based treatment and prolonged infusion) and other forms of non-surgical 
therapy (cryosurgery etc.). 
 
 This option would be contrary to the weight of world-wide evidence supporting liver 
resection as the only potentially curative treatment option for this patient group. Liver 
resection is offered as a standard treatment across the world and it is extremely unlikely, 
from an ethical viewpoint, that any future RCT will be conducted for patients with solitary 
metastases or multiple unilobar disease. There may be potential for further studies 
(preferably RCTs) of more aggressive forms of liver resection for patients with much 
more dispersed disease, with high levels of liver involvement or evidence of certain types 
of extrahepatic disease. 
 
The authors of this Guidance Note recommend: Option 2. 
 
Additional recommendation 
 
The benefits and cost-effectiveness of regular follow-up of colorectal patients should be 
considered as part of a RCT. 
 
The cost-effectiveness of non-surgical treatment of liver secondaries for colorectal cancer 
should be evaluated as there appears to be little reliable information on this subject. 
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5. DISCUSSION AND CONCLUSIONS 
 
5.1 Lack of Randomised Evidence Base 
 
There is an obvious issue about the lack of RCT data in the case of liver resection. This lack 
of such trial data probably relates to the fact that simple liver resections have been 
performed for a great number of years and have become an accepted potentially curative 
technique. The following questions remain: 
 
 Are randomised trial data still necessary in making policy decisions in respect of liver 
resection?  
 If needed, can they be provided technically?  
 If so, can they be realistically expected?  
 
The answer in the case of simple resection, such as, single metastasis or multiple unilobar 
disease, is that RCT evidence is unlikely to be necessary, as the survival benefits have been 
clearly established from the observational data taken over a significant period of time. Also, 
the randomised trial data of conventional treatment show only marginal patient benefits. Any 
suggestion of randomising such patients would be likely to run into ethical problems given 
this evidence-base. However, it is true that not all patients who could benefit from simple 
liver resection are actually receiving such treatment. 
 
For more complex liver surgery, there is less clear evidence of effectiveness and in these 
cases it is fair to say that randomised trial evidence might contribute to the debate, although 
there may be difficulties in patients’ acceptance of randomisation to non-surgical treatment if 
the metastases are technically resectable. Other issues including adjuvant chemotherapy 
following resection and the combination of resection with cryosurgery are also clear areas 
where future randomised evidence is needed. 
 
5.2 Comparative Use of Resection for Other Cancers 
 
Resection is also used as a potentially curative surgical technique for other cancers, in 
particular cases of pancreatic, oesophageal and other gastrointestinal cancer.   
 
Resection for pancreatic cancer appears limited to around 10-15% of patients depending on 
the amount of tumour spread, as is the case for liver resection. Median survivals are 
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reported at around 18-20 months and five-year survivals are noted at around 10%.
45
 For 
cases of oesophageal cancer, five-year survival ranges between 20%-30%.
46
 
  
From the available evidence base, liver resection would seem to provide at least 
comparable benefits to the use of resection in other cancers. 
 
5.3 Can a Set of Indicators be Established Which Clearly Identifies Patients for 
Referral from District General Hospitals? 
 
It is still difficult to determine a precise definition of ‘suitable’ patients for liver resection. 
Many of the prognostic factors suggested in the literature are post-operative or rely on 
imaging techniques conducted during surgery. The evidence suggests that those patients 
most suited to resection are likely to have: 
 
 single metastasis, no extrahepatic disease; 
 multiple metastases, restricted to a single lobe, no extrahepatic disease.  
 
Given the typical patient profiles of the resection series, this is likely to equate to around 
10% of those with liver metastaes. 
 
In all cases the survival will be strongly influenced by the ability of the surgeon to remove the 
tumour(s) clearly without any involvement in the resection margins. Importantly the clinical 
experience of the authors suggests that rates of unnecessary laparotomy are likely to be 
very low indeed (in contrast to some studies). 
 
There needs to be a clear set of referral guidelines for district general hospitals when 
dealing with cases of liver metastases. These guidelines should define clearly the treatment 
pathways open to the patient. Suggested referral guidelines have been included in the 
appendices. 
 
5.4 Service Provision 
 
If liver resection is to be provided for a group of patients with suitable physical status and 
liver involvement, then there are a number of operational issues which will need to be 
considered carefully: 
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 Is there a need to introduce a more formal follow-up procedure for colorectal cancer 
patients after surgery for the primary tumour? 
 
 Is there a case to train staff and equip local district general hospitals to conduct liver 
resection procedures or should treatment be based on more experienced centres? 
 
 What should be considered as a sufficient volume of resections to maintain a clinical 
specialism? 
 
Based on the clinical experience of one author (Ali Majeed) it is estimated that a typical 
hepatic surgeon, specialising in liver resections, could reasonably be expected to conduct 
around 50 resections per annum. Ideally, a specialist centre would have two or more 
surgeons. 
 
5.5 Use of Repeat Liver Resection for Liver Only Recurrences  
 
A number of the reported case-series have used repeated resection, or re-resection, in 
cases of recurrence which has been restricted to the liver only. Up to 70% of initially 
resected patients are expected to have some form of recurrence, and in only 10-15% of 
cases is this restricted to isolated liver cancer. Therefore, the volume of such re-resection 
patients is relatively low, with less than 20 such cases expected in the Trent region each 
year, even if all potentially resected patients are in fact initially resected. From the available 
evidence, the outcomes from re-resected patients appear positive with no additional 
operative mortality above that of first-time resection. 
 
5.6 Likely Costs of Providing Liver Resection 
 
Overall, it has been estimated that for every 10,000 colorectal patients who have additional 
liver metastases, roughly 10% will be suitable for initial surgical resection with curative 
intent. Given the average cost of resection of £64,070 it is estimated that the marginal costs 
of providing liver resection for this group of patients are around £6,400,000 (equating to 
£130-135,000 for an average district of 500,000 population).  
 
If the criteria for resections were to be widened, this figure could rise to around £12,800,000 
(or £260-£270,000 for a ‘typical’ district) representing 20% of all patients with metastatic 
disease  
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Appendix A Description of Key Resection Case-series 
Reference Country Pubn 
Year 
Time 
Period 
Yrs  No 
Sites 
Design Method  No 
Pts 
Age 
Profile
a
 
Description Resections Adj Follow-up 
           Potentially 
Curative  
Type  Median 
(mths) 
Cover 
Ohlsson et al.
23
 SWE 98 71-95 24 1 Retrospective 
(Prospective 
since 1980) 
Hospital records review 111 37%<60 No EHD, limited number of mets /  intra op 
clear of tumour 
100% 77% anatomic  
 17% atypical minor  
 5% atypical major 
18% 60.2 100% 
Bakalakos et al. 
27
 US (Ohio) 98 78-93 15 1 Retrospective Hospital records review 301  61(25-83) Intra op clear of tumour and EHD befined 
curative 
79% 80% wedge  
 20% lobectomy  
100% NS 86% 
Fong et al. 
29
 US (MSK) 97 
 
85-91 6 1 Retrospective Hospital records review 456 62(27-87) No EHD / intra op clear of tumour 100% 27% wedge 
 13% segmental  
 3% lateral 
segmental   
 44% lobectomy  
 13% extended   
NS 37 NS 
D'Angelica et al.
36
 
(subset of the same pt 
group as Fong et al.) 
US (MSK) 97 
 
85-91 6 1 Retrospective Hospital records review 96 16%>70 Study of prognostic factors in >5 year 
survivors of resection 
 
100% 43% lobectomy 
47% wedge (or 
less) 
10% extended 
NS NS NS 
Rees et al.
24
 UK 97 86-96 9 1 Prospective Hospital records review 107 NS Pre-op no EHD / intra-op  assessment  of 
resectablity using  ultrasongraphy  
 
83% 89% anatomic 
5% atypical/wedge 
NS (12-108)  100% 
Jenkins et al. 
28
 US (Illinois) 97 75-93 18 1 Retrospective Hospital records review + 
telephone follow-up 
 
131  62(30-88) Curative resection defined as no EHD, >1cm 
negative margins 
 
81% 70% anatomic  
 30%  wedge 
 
NS 24  NS 
Taylor et al. 
30
 Canada 97 77-93 16 1 Retrospective Hospital records review 123 58(30-87) No EHD / intra-op expectation of 1cm margin  
<5 metastases/ unclear if subsequent positive 
tumour margins were excluded. 
100% 84% anatomic 60% NS 95% 
Jaeck et al.        
(subset of Nordlinger 
et al.)
18
 
France 97 59-87 28 85 Retrospective Questionnaire survey of      
long-term survival and 
prognostic data ( > 5 years) 
747 58
 Mean
  Survival considered for 1818 curative 
resections. Prognostic analysis restricted to 
curative resection up to 1987 (i.e. at least 5 
years follow-up).  
100% 63% major 
37% minor 
32% NS 100% 
Nordlinger et al.
19
 France 96 68-90 22 85 Retrospective Questionnaire survey of 
overall survival 
1568 46%<60 Post-op exclusion of EHD and incomplete 
resection and follow up. 
100% 64% major  
36% minor 
35% 19 97% 
Wade et al.
15
 US  96 88-92 14 85 Retrospective Central patient 
administration database 
(22,000 pts) 
161 64 
mean
 Complex inclusions based on diagnostic ICD 
and op codes confirm  hepatic metastases 
and liver resection / synch metastases 
excluded 
NS 57% anatomic 
 
NS NS NS 
Fuhrman et al. 
26
 US (Texas) 95 88-92 14 1 Retrospective Hospital records review 
 
151 58(?) Pre-op no EHD.  Intra-operative assessmet of 
resectablity using ultasonography,  >4 
metastases excluded. 
71% 65%  anatomic NS 25 NS 
Scheele et al.
25
 Germany 95 60-92 32 1 Retrospective Hospital records review 
 
469 59(26-91) 469 patients had curative intent / 434 had 
potentially curative procedure / 350 survived 
curative resection 
100% 45% common 
anatomic 
 34% uncommon 
anatomic 
21% non-anatomic 
7% NS 99% 
Gayowski et al.
31
 US (Pitts) 94 81-91 11 1 Retrospective  Hospital records review / 
telephone survey / records 
204 60(28-79) Resections had curative intent. although no 
clear criteria provided 
100% 84% major 
16% minor 
NS 69 NS 
 
a
 Assume average ages to be median statistics unless expressly indicated otherwise  
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Reference Country Pubn 
Year 
Time 
Period 
Yrs  No 
Sites 
Design Method  No 
Pts 
Age 
Profile
a
 
Description Resections Adj Follow-up 
           Potentially 
Curative  
Type  Median 
(mths) 
Cover 
review 
Van Ooijen et al.
20
 Netherland 92 79-89 10 15 Retrospective Hospital records review 
 
118 57(28-83) Pre-op exclusion of  EHD, intra-op exclusion 
of macroscopic disease 
100% 74% anatomic 
22% wedge 
4% combined 
NS NS 99% 
Rosen et al. 
33
 
(prev reported by 
Adson & Wagner et 
al.) 
US (Mayo) 92 60-87 27 1 Retrospective Hospital records review 280  59(?) No EHD and all known tumour removed with 
negative >1cm margins - potentially curative 
resections 
100%  NS NS 97% 
Cady et al.
47
 US (Boston) 92 up to 90 NS 1 Retrospective  Hospital records review 142  61(31-80) 129 survived and were considered curative 
procedures. Involved use of cryosurgery in 
13% of patients 
91% NS NS NS NS 
Fegiz et al.
48
 Italy 91 NS NS NS 
(>1) 
Retrospective  NS 212 NS Pre-op exclusion of EHD 100% 47% major 
53% minor 
NS NS NS 
Doci et al.
32
 Italy 91 80-89 10 1 Retrospective Hospital records review 100  57(28-74) Excluded EHD, >1cm clear margin, no gross 
residual disease 
100% 50% lobectomy  
50% non-anatomic 
NS NS 100% 
Steele et al.
21
 US (Boston) 91 84-88 4 15 Prospective Hospital records review 150 63%>60 12% non-curative  
42% no resection 
46% 37% wedge NS 37 100% 
Schlag et al.
39
 Germany 90 81-89 8 1 Retrospective Hospital records review 122  59(36-79) No EHD, single lobe and < 4 metastases 
Study of synchronous vs. metachronous 
100% 37% single lobe 
seg 
23% wedge 
35% right or left 
hemi 
NS 22 100% 
Hughes et al.
22
 US   
(Registry of  
Heaptic 
Metastases) 
86 48-85 37 24 Retrospective Registry data on curative 
resections 
859 13%>70 Group 1 : 24  patients - presence of nodes 
Group 2 : 37 patients - presence of EHD 
Group 3 : 798 - curative removal of isolated 
metastases 
93% 41% major 
anatomic 
 35% wedge 
24% minor 
anatomic 
NS 21 100% 
 
NS - Not stated 
21 studies which provide unique survival and/or prognostic data 
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Appendix B  Summary of Survival Outcomes (all patients) 
Reference Period Outcome Group Overall Survival Disease-free 
Survival 
Operative 
Mortality
Excluded 
Complication  
Rate  
Operative 
Mortality 
   Median 3  Yr 5 Yr 3 Yr 5 Yr    
Ohlsson et al.
23
 71-95 Curative 25 mths 37% 25% 22% 19% NS 14% 3.6% 
 71-84 Curative 20 mths  19%  18% NS  6% 
 85-95 Curative 40 mths  35%  21% NS  0% 
Bakalakos et al.
27
 78-93 All 20 mths      17% 1.1% 
  Curative 23 mths        
  Non-curative 15 mths        
  Non-resected 13 mths        
Fong et al.
29
 85-91 Curative 46 mths 59% 38%    24% 2.8% 
Rees et al.
24
 86-96 All NS 47% 30% NS NS NS 17% 1% 
  Curative NS 56% 37%      
  Non-curative NS 11% 6%      
Jenkins et al.
28
 75-93 All  33 mths 42% 25% 34% 16% NS 18% 3.8% 
  EHD  NS  0%      
  + Margins  NS  0%      
  Synchronous NS  13%      
  Metachronous NS  35%      
Taylor et al.
30
 77-93 All NS  34%  20% NS 28% 0% 
  1 metastasis NS  47%      
  > 1 metastasis NS  17%      
  1 met + sat nodes NS  16%      
Nordlinger et al.
49
 68-90 All NS 44% 28% 23% 15% Yes 23% 2.3% 
  0-2 risk factors
b
 NS 79%       
  3-4 risk factors
b
 NS 60%       
  5-7 risk factors
b
 NS 43%       
           
           
 
b  
2-year survival data not 3-year 
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Reference Period Outcome Group Overall Survival Disease-free 
Survival 
Operative 
Mortality
Excluded 
Complication  
Rate  
Operative 
Mortality 
   Median 3  Yr 5 Yr 3 Yr 5 Yr    
Fuhrman et al.
26
 88-92 All NS  31%      
  Curative NS  44%     2.8% 
  Un-resected 
Resected 
NS  0%      
Wade et al.
15
 88-92 All 31 mths  26%   NS  4% 
Scheele et al.
25
 60-92 All NS 45% 33%   No 16% 4.4% 
  Curative 40 mths  38%  33%    
Gayowski et al.
31
 81-91 Curative 33 mths 43% 32% 29% 25%   0% 
Van Ooijen et al.
20
 79-89 Curative NS  21%  19%  34% 5% 
Rosen et al.
33
 60-87 Curative 32 mths 47% 25%    NS 2% 
Fegiz et al.
48
 NS Curative NS     NS NS 6.8% 
  1 metastasis NS 34% 20%      
  > 1 metastasis NS 17% 17%      
  Synchronous NS 44% 18%      
  Metachronous NS 32% 22%      
Doci et al.
32
 80-89 Curative 28 mths  30%  11% Yes 33% 5% 
  Dukes B 43 mths  47%      
  Dukes C 27 mths  24%      
Steele et al.
21
 84-88 All       13% 2.7% 
  Curative 37 mths  NS      
  Non-cure 21 mths  NS      
  Un-resected 17 mths  NS      
Schlag et al.
39
 81-89 Curative NS  NS    29% 4% 
  Metachronous 32 mths  16%     6.7% 
  Synchronous 24 mths  2%     0% 
Hughes et al.
17
  All   33%  21%    
  Curative    33%  22%    
 
NS - Not stated 
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Initial Presentation with Colorectal Cancer
Discuss with liver surgeon if complete resection of primary
Refer for further assessment of liver lesions
Assess lesions at laparotomy
Laparotomy if appropriate
Liver metastases
Colonoscopic follow-up as indicated
No recurrence
Refer for palliative chemotherapy
Extrahepatic disease
Refer for liver assessment
No extrahepatic disease
CT chest and abdomen
Liver metastases on Ultrasound
Raised CEA level
6 monthly Ultrasound Scan of Liver. CEA Level For Two Years
Resect primary and confirm liver clear at laparotomy
Liver clear
Preoperative ultrasound of liver and CEA level
Yes
Treat primary lesion as appropriate.  No follow-up is indicated
No
Would patient be fit for surgical resection of recurrent disease ?
 
  
Appendix D  Prognostic Factors Restricted to Latest Reports of Individual Case-series  
(17 papers) that Provide Information on Prognostic Factors 
M = significant from a multivariate analysis / U = significant from a univariate analysis / X = considered, but not significant 
References 
 
Age Sex No. of 
Mets 
(>3) 
Satellite 
Nodes 
Size 
of 
Mets 
Bilobar vs. 
Unilobar 
Synchronous 
vs. 
Metachronous 
Time 
interval  
Primary to 
LM 
Grade of 
Liver 
Tumour 
Extrahepatic 
Disease 
(EHD) 
Serosa 
infiltration 
Positive 
Margins 
(>1cm) 
Pre-op 
CEA 
values 
(>200) 
% Liver 
Removed 
PLR 
Stage 
of 
Primary 
Site of 
Primary 
Presence 
of Primary 
Nodes 
Type of 
Resection -  
(anatomical) 
Blood 
Transfusion 
Year of 
Resection 
Ultrasound 
Dissector 
Method of 
Detection 
Ohlsson et al.
23
   X X X X X  M M  U M  X   X M M U U 
Bakalakos et al.
27
   X  X M  X    M   X   X X    
D'Angelica et al.
 36  c
 X M X  X M  X  X  M X  X X  X     
Fong et al.
29
 X X M  M U  M  M  M U  U X U U X    
Rees et al.
24
   X  M X X     M   X U       
Jenkins et al.
28
 X X X    M   M  M  X  X  X X    
Taylor et al.
30
 X X M M X  X X         X X U    
Jaeck et al.
50
 X X X  X X X   M M M M   X  X     
Nordlinger et al.
49
 M  M  U   M   M M M  M  M      
Scheele et al.
51
 X X X M M X M X M U  U U  M X U M  M   
Gayowski et al.
31
 U  M  X U U U  U  M   U   X X    
Van Ooijen et al.
20
  
c
  X M   X X     X   X X  X M    
Rosen et al.
33
  X M U X  U   M     U X      M 
Cady et al.
52
  
c d
   U  U U      U U U        U 
Fegiz et al.
48
  
e
 X X U   U U  U     U U   X     
Doci et al.
53
 X U X   U  X M    X  U M  U     
Hughes et al.
17
 X  M   X  M  M  M X  U  M      
 
Mets - Metastases 
 
c
 Prognostic factor related to Disease-free Survival not Overall Survival 
d
 univariate analysis only 
e
 evaluated against 3 year overall survival 
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Appendix E 
EXAMPLE OF A PROTOCOL FOR THE FOLLOW-UP OF PATIENTS WITH 
COLORECTAL CANCER WITH SPECIAL REFERENCE TO LIVER METASTASES 
 
The colorectal surgeon receives the initial referral and investigates the patient.  A key 
determinant of follow-up is whether the patient would be fit for resection of recurrent disease 
if it is found.  Pre-operative liver ultrasonography and determination of CEA levels should be 
carried out once the diagnosis is confirmed.  Resection of the primary should then be 
carried out. 
 
Synchronous Metastases: 
If metastases are discovered before resection of the primary lesion, colo-rectal surgery 
should proceed and the metastases be assessed.  A key determinant of the success of 
hepatic resection is the clearance of the primary tumour.  If the colorectal surgeon considers 
that residual macroscopic disease is present, the patient should be referred for 
chemotherapy directly after surgery. If the surgeon considers that the primary colonic cancer 
has been satisfactorily cleared, and the liver disease is not widespread, patients (of all 
Dukes stages) should be referred directly for hepatic resection and this will be followed by 
systemic chemotherapy.  Further management of rectal cancer patients will depend on 
radial resection margins in rectal cancer.  Involved margins have a high incidence of local 
recurrence and these patients should be referred for systemic chemotherapy or radiotherapy 
and subsequent hepatic resection if imaging confirms the absence of local recurrence.   
 
Metachronous Metastases: 
If metastases are not found pre-operatively, colorectal surgery is conducted and entry into 
one of the adjuvant chemotherapy trials may be considered. 
Follow-up of patients with no metastases at the time of removal of the primary is conducted 
in the colorectal clinic.  The following protocol is recommended (in addition to the colonic 
surveillance program):  
6-monthly follow-up for two years  (90% of patients who develop liver metastases will 
do so within two years of diagnosis of colorectal cancer). At each visit:    
 Ultrasonography of the liver 
 56 
 Serum CEA level 
At any stage of follow-up if the ultrasounds scan or CEA is abnormal, a Computed 
Tomography (CT) scan of the chest and abdomen should be performed.  If there is no 
evidence of extrahepatic disease, and liver metastases are confirmed, the patient should be 
referred for further assessment of the liver lesions with a view to resection. 
 
A ‘wait and see’ policy will result in metastases enlargement and hepatic lymphatic spread 
and is no longer justified. 
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Appendix F 
EXAMPLE OF GUIDELINES FOR REFERRAL FOR HEPATIC RESECTION 
 
The patient should be referred for consideration of liver resection only if the following criteria 
are fulfilled: 
 The patient is fit to undergo hepatic resection (ASA I and II.  Rarely ASA III).  The 
morbidity of hepatic resection is low (e.g. same as gastrectomy). 
 There is no evidence of extrahepatic disease. 
These criteria are best assessed by: 
 Anaesthetic assessment by Consultant Anaesthetist; 
 Computed Tomography (CT) Scan of the chest and abdomen. 
 
Assessment of Liver Metastases: 
Resectability of metastases depends upon their geographical distribution in the liver.  Size 
and number are not relevant.  It is recommended that the CT scan should be sent to the 
liver surgeon for assessment and a decision can be made as to whether further imaging is 
appropriate. 
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